SynthesisBMC infectious diseases2020
Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Seroprotection after measles vaccination in children with sickle cell anemia receiving hydroxyurea.Blood advances · 2026Observational
- Review
- Completeness of MMR Vaccination and Durability of Vaccine-Induced Antibody Responses in Children with Inflammatory Bowel Disease.Biomedicines · 2026Article
- Factors influencing post-vaccination antibody levels to measles and rubella in children with inflammatory bowel disease.Immunologic research · 2026Observational
- Investigation of a measles outbreak in a highly vaccinated middle school, France, 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Article
- Factors associated with measles vaccine immunogenicity in children at University Teaching Hospitals, Lusaka, Zambia.PLOS global public health · 2025Article
- Unveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination.The Lancet regional health. Southeast Asia · 2025Article
- Serosurveillance for Measles and Rubella.Vaccines · 2024Review
- Dynamics of measles immunity from birth and following vaccination.Nature microbiology · 2024Article
- Immunogenicity and reactogenicity following MMR vaccination in 5-7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants.EClinicalMedicine · 2024Article
- Seroprevalence of measles antibody among immigrants in Gwangju, South Korea.Frontiers in public health · 2024Article
- Mathematical modeling and dynamics of immunological exhaustion caused by measles transmissibility interaction with HIV host.PloS one · 2024Article
- Two-dose measles-rubella vaccine schedule for measles-rubella elimination.The Indian journal of medical research · 2023Article
- Less than one-fifth of Ethiopian children were vaccinated for measles second dose; evidence from the Ethiopian mini demographic and health survey 2019.Vaccine: X · 2022Article
- Measles epidemic in Southern Vietnam: an age-stratified spatio-temporal model for infectious disease counts.Epidemiology and infection · 2022Article
- Biological Profile and Clinical Features as Determinants for Prolonged Hospitalization in Adult Patients with Measles: A Monocentric Study in Western Romania.Pathogens (Basel, Switzerland) · 2022Article
- Updates on Measles Incidence and Eradication: Emphasis on the Immunological Aspects of Measles Infection.Medicina (Kaunas, Lithuania) · 2022Review
- Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age.BMC immunology · 2022Article
- Determination Factors Associated with Immune Responses Towards First Dose Edmonston-Zagreb (EZ) Measles Vaccine in Indonesian Infants.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objectives of this review were to evaluate the effect of age at administration of the first dose of a measles-containing vaccine (MCV1) on protection against measles and on antibody response after one- and two-dose measles vaccinations.
methodsWe conducted a systematic review of the PubMed/MEDLINE, Embase, Web of Science and Cochrane databases (1964-2017) to identify observational studies estimating vaccine effectiveness and/or measles attack rates by age at first vaccination as well as experimental studies comparing seroconversion by age at first vaccination. Random effect models were used to pool measles risk ratios (RR), measles odds ratios (OR) and seroconversion RR of MCV1 administered at < 9, 9-11 or ≥ 15 months compared with 12 or 12-14 months of age.
resultsWe included 41 and 67 studies in the measles protection and immunogenicity analyses. Older age at MCV1, from 6 to ≥15 months, improved antibody response and measles protection among one-dose recipients. Pooled measles RR ranged from 3.56 (95%CI: 1.28, 9.88) for MCV1 at < 9 months to 0.48 (95%CI: 0.36, 0.63) for MCV1 at ≥15 months, both compared to 12-14 months. Pooled seroconversion RR ranged from 0.93 (95%CI: 0.90, 0.96) for MCV1 at 9-11 months to 1.03 (95%CI: 1.00, 1.06) for MCV1 at ≥15 months, both compared to 12 months. After a second dose, serological studies reported high seropositivity regardless of age at administration of MCV1 while epidemiological data based on few studies suggested lower protection with earlier age at MCV1.
conclusionsEarlier age at MCV1 decreases measles protection and immunogenicity after one dose and might still have an impact on vaccine failures after two doses of measles vaccine. While two-dose vaccination coverage is most critical to interrupt measles transmission, older age at first vaccination may be necessary to keep the high level of population immunity needed to maintain it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.